Efficacy Of Education And Advice Delivered By Text Message To Aid Smoking Cessation
Funder
National Health and Medical Research Council
Funding Amount
$538,395.00
Summary
A high proportion of smokers indicate a desire to stop smoking and report having made attempts to quit. However, most attempts are not successful and new methods are needed to support motivated smokers and improve success rates. This project evaluates the use of text messages to deliver advice and support to smokers motivated to stop smoking. We aim to understand if and how this promosing new intervention helps smokers to quit.
Public Health Policies And Interventions To Reduce Tobacco-related Harms Among Socially Disadvantaged Populations And ‘low Probability Quitters’
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
Tobacco continues to be a leading cause of preventable death and disease in Australia. Those who are socially disadvantaged are at higher risk of smoking, which contributes to the health gap between the rich and poor. This research will provide evidence for policy makers on interventions which could reduce smoking among the most disadvantaged in society. It will also examine whether less harmful nicotine products could a reduce health risks in smokers who find quitting difficult.
An Open-label Randomised Pragmatic Policy Trial Of Nicotine Products For Short-term Cessation Assistance Or Long-term Substitution In Smokers.
Funder
National Health and Medical Research Council
Funding Amount
$1,053,910.00
Summary
Many smokers who try to quit fail in their attempt. Medicinal nicotine is currently only used as a short-term quit aid. This trial will test if offering smokers the option of using these products as long-term substitutes for cigarettes will help more smokers to successfully quit. We will also determine if offering smokers low toxicity smokeless tobacco and electronic nicotine devices in addition to medicinal nicotine products further increases the number of smokers who quit successfully.
Title: ‘Indigenous Counselling And Nicotine (ICAN) QUIT In Pregnancy’ - A Cluster Randomised Trial To Implement Culturally Competent Evidence-based Smoking Cessation For Pregnant Aboriginal And Torres Strait Islander Smokers
Funder
National Health and Medical Research Council
Funding Amount
$2,259,016.00
Summary
‘ICAN QUIT in Pregnancy’ tackles smoking through training health providers caring for expectant mothers of Indigenous babies in real-world primary care settings. The intervention was co-developed with Aboriginal communities. We will assess how many Indigenous women, cared for by the trained services, quit smoking, compared to the women that receive usual care. We anticipate that babies born to mothers in the intervention group will have less respiratory illness in their first six months.
Translating Evidence Based Smoking Cessation Care For Pregnant Indigenous Smokers
Funder
National Health and Medical Research Council
Funding Amount
$181,065.00
Summary
Smoking is a major cause of poor health in mothers and babies, yet smoking rates remain high in Indigenous pregnant women. This fellowship supports a trial of a culturally competent targeted intervention for Indigenous pregnant women who smoke. The intervention provides webinar training of health providers in participating Aboriginal Medical Services. A control group will use their standard care practices. Smoking rates of the women cared for by health providers in each group will be compared.
Smoking Cessation And Bone Health: Observational And Intervention Studies In Twins And A Quitline Population
Funder
National Health and Medical Research Council
Funding Amount
$639,050.00
Summary
Osteoporosis is a major health problem that causes bones to break (fracture) easily. Many bones are susceptible, with hip fractures being the worst outcome of osteoporosis. They cause pain, disability, require major health interventions (surgery and rehabilitation), lead to death in about 20% of cases, and the overall care of hip fracture patients is very expensive. Osteoporosis is treated to reduce the risk of fractures. The prevention and treatment of osteoporosis should include avoidance of f ....Osteoporosis is a major health problem that causes bones to break (fracture) easily. Many bones are susceptible, with hip fractures being the worst outcome of osteoporosis. They cause pain, disability, require major health interventions (surgery and rehabilitation), lead to death in about 20% of cases, and the overall care of hip fracture patients is very expensive. Osteoporosis is treated to reduce the risk of fractures. The prevention and treatment of osteoporosis should include avoidance of factors known to bring on or worsen the condition. Smokers are known to have an increased risk of osteoporosis and fractures. However, it is not known how smoking brings on osteoporosis. Importantly, neither is it clear whether quitting smoking leads to improved bone health (and a reduced risk of fractures). These are important questions for the community in general and for smokers with osteoporosis in particular. We will endeavour to answer these questions by studying twins who do and do not smoke and by observing what happens to measures of bone health (bone mineral density and other factors) in people attempting to quit smoking. New information gained from these studies may lead to better ways of avoiding or treating the damage that smoking does to bone. We may also become able to predict the benefit to bone when people quit smoking.Read moreRead less
A Pragmatic Randomised Clinical Trial Of Nicotine Vaporisers Added To Smoking Cessation Treatment For Priority Populations Living With Comorbidities
Funder
National Health and Medical Research Council
Funding Amount
$1,499,145.00
Summary
Smoking is a leading cause of early death for people with certain health conditions because they are more likely to smoke and are also at greater risk of tobacco-related disease. This clinical trial will test whether encouraging people living with Hepatitis C Virus, people on opiate substitution therapy and people living with HIV who smoke to use nicotine vaporisers long-term, in addition to current smoking cessation treatments, will help them to stay abstinent from smoking.
Unintended Adverse Effects Of Advertising For Nicotine Replacement Therapies
Funder
National Health and Medical Research Council
Funding Amount
$133,250.00
Summary
Advertising for certain pharmaceutical products (nicotine replacement therapy( NRT)) to help people quit smoking has been permitted in Australia since 1997. Zyban, an antidepressant drug, has been found to be helpful in quitting smoking, but advertising has not yet been permitted in Australia although it is allowed overseas. Because such advertising will reach more than the primary target group of heavy smokers ready to quit, it is important to consider the responses of other smokers who are not ....Advertising for certain pharmaceutical products (nicotine replacement therapy( NRT)) to help people quit smoking has been permitted in Australia since 1997. Zyban, an antidepressant drug, has been found to be helpful in quitting smoking, but advertising has not yet been permitted in Australia although it is allowed overseas. Because such advertising will reach more than the primary target group of heavy smokers ready to quit, it is important to consider the responses of other smokers who are not ready to quit and those at risk of taking up smoking. There is concern that there may be 'boomerang' effects, albeit unintended, on these population groups, because they may feel reassured that there is an effective method to quit and so be in no rush to quit soon, they may try to quit using these products before they are really ready, and in the case of teenagers, they may think that these products make it easy to quit, so there is less problem with starting to smoke. In order to assess if this is so, we will randomly allocate smokers not yet ready to quit and teenagers to either (a) a group where they view 3 ads promoting non-drug methods of quitting, such as the Quitline, (b) a group where they view 3 ads promoting the NRT gum or patch, or (c) a group where they view 3 ads promoting Zyban as a method for quitting. The study will use questionnaires to assess whether, compared with those viewing the non-drug anti-smoking ads, those viewing the NRT or Zyban ads think smoking is less addictive and have less intention to quit, or in the case of teenagers, have more intention to take up smoking. This project will be the first formal study to assess whether there may be adverse effects of NRT and Zyban advertising on smokers not yet ready to quit and teenagers who are not already regular smokers. For this reason, the study will help an assessment of the risks of such advertising compared with the established benefits for smokers who are ready to quit.Read moreRead less
Prevention And Treatment Of Bone Infection With CSA-90
Funder
National Health and Medical Research Council
Funding Amount
$350,983.00
Summary
Bone infections are a major challenge to treat, especially with the rise of drug resistant “superbugs”. We have access to a new agent, CSA-90, that has dual properties of being anti-microbial (antibiotic) and helps encourage bone growth. This project aims to expand upon our prior research and test CSA-90 for the treatment of chronic bone infections. We will also look at applying this technology to joint replacements and this drug may be particularly useful for coating orthopaedic implants.